Objective To evaluate the efficacy, toxicity and clinical benefit response of gemcitabine on advanced non small cell lung cancer in elderly. Methods Patients in the chemotherapy arm of the study received gemcitabine 1 250 mg/ m 2 as a intravenous infusion every 21 days .Patients in the best supportive care(BSC) arm should not receive chemotherapy or anticancer therapy. Results Overall survival period in the gemcitabine arm was significantly longer than in the BSC arm ( P

Objective To observe the inhibitory effect of ethanol extract of Cassia mimosoides Linn. (EE-CML) on dimethylnitrosamine-induced hepatic fibrosis in rats and to explore its therapeutic mechanism. Methods Sixty male SD rats were equally divided into 6 groups: normal group, model group, high-, middle-and low-dose EE-CML groups (at the doses of 12.6 g/kg, 4.2 g/kg, and 1.4 g/kg respectively) and colchicine (0.2 mg/kg). Intervention treatment with EE-CML by gastric gavage was carried out in the rats with hepatic fibrosis which was induced by dimethylnitrosamine simultaneously and their effects were compared with the group treated with colchicine. The model group and the normal group were given the same volume of saline once a day. Four weeks after treatment, hepatic function, levels of serum hyaluronic acid (HA), serum laminin (LN), serum aminoterminal propeptide of type III procollagen (PCIII), hepatic hydroxyproline (Hyp), and histopathological changes in rats were assayed and examined. Results Compared with those in the model group, in the differences of serum alanine aminotransferase (ALT) level in three EE-CML groups and serum aspartate aminotransferase (AST) level in high dose EE-CML group were statistically significant (P

Objective To observe the inhibitory effect of ethanol extract of Cassia mimosoides Linn. (EE-CML) on dimethylnitrosamine-induced hepatic fibrosis in rats and to explore its therapeutic mechanism. Methods Sixty male SD rats were equally divided into 6 groups: normal group, model group, high-, middle-and low-dose EE-CML groups (at the doses of 12.6 g/kg, 4. 2 g/kg, and 1.4 g/kg respectively) and colchicine (0. 2 mg/kg). Intervention treatment with EE-CML by gastric gavage was carried out in the rats with hepatic fibrosis which was induced by dimethylnitresamine simulta-neously and their effects were compared with the group treated with colchicine. The model group and the normal group were giv-en the same volume of saline once a day. Four weeks after treatment, hepatic function, levels of serum hyaluronic acid (HA), serum laminin (LN), serum aminoterminal propeptide of type Ⅲ procollagen (PCⅢ), hepatic hydroxyproline (Hyp), and histopathological changes in rats were assayed and examined. Results Compared with those in the model group, in the differences of serum alanine aminotransferase (ALT) level in three EE-CML groups and serum aspartate aminotrans-ferase (AST) level in high dose EE-CML group were statistically significant (P < 0. 05) ; hepatic Hyp level and serum HA, LN and PCⅢNP contents in EE-CML groups were significantly lower than those in the model group (P < 0. 05). Hepatic fi-brosis of rats in EE-CML groups alleviated significantly, and the differences compared with that in the model group were sta-tistically significant (P < 0. 05). Conclusion Ethanol extract of Cassia mimosoides shows significant inhibitory effect on the dimethylnitrosamine-induced hepatic fibrosis in rats, and the inhibitory mechanism may be related to the protection on hepatic cells and the inhibition on collagen fiber synthesis.

OBJECTIVETo observe the effects of electroacupuncture (EA) with different frequencies based on the western conventional treatment and rehabilita tion training for stroke dysphagia.

METHODSSixty patients with dysphagia after stroke were randomized assigned into a low frequency (2 Hz) group and a high frequency (100 Hz) group, 30 cases in each one. Basic treatment was applied in the two groups. The acupoints were Fengfu (GV 16) and Lianquan (CV 23). EA with continuous wave and tolerant intensity were connected for 30 min, once a day for 14 days. The main index was video fluoroscopic swallowing study (VFSS) to detect passing time at oral stage, pharynx delay time at pharyngeal stage, passing time at pharynx stage. The second indexes were water swallow test rating and standardized swallowing assessment (SSA). The clinical effect was evaluated.

RESULTSAfter treatment, the passing time at oral stage, pharynx delay time at pharyngeal stage, passing time at pharynx stage were lower than those before treatment in the two groups (all<0.05), and the results in the low frequency group were better (all<0.05). After treatment, the water swallow test rating improved in the two groups (both<0.05), and that in the low frequency group was better (<0.05). The SSA score decreased in the two groups (both<0.05), and the improvement in the lower frequency group was superior to that in the high frequency group (<0.05). The total effective rate in the low frequency group was 93.3% (28/30), which was better than 66.7% (20/30) in the high frequency group (<0.05). .

CONCLUSIONThe effect of EA with lower frequency is better than that of EA with higher frequency for stroke dysphagia.